![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Chemotherapy is an important part of treatment for patients with gastric cancer. Although there is no single globally accepted standard of care for patients with advanced disease, regimens typically include a fluoropyrimidine and a platinum compound with or without a third drug (usually epirubicin or docetaxel). Oral fluoropyrimidines, such as capecitabine, offer clear advantages to patients in terms of convenience, but it is only recently that comprehensive data on their efficacy and safety in patients with gastric cancer have become available. The present article reviews capecitabine in the treatment of advanced and resectable gastric cancer. Ongoing Phase III trials involving capecitabine are also discussed. The data show that capecitabine is now established as an integral part of the multi-agent regimens used in the management of patients with gastric cancers.
Financial & competing interests disclosure
Y-J Bang has served as a consultant and received honoraria and research grants from F Hoffmann La-Roche Ltd. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Writing assistance was provided by Lee Miller (Miller Medical Communications), which was funded by F Hoffmann-La Roche Ltd.